Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023)
Sol-Gel Technologies (SLGL) reported Other Non Operating Income of $2.1 million for Q4 2023, up 14564.29% quarter-over-quarter from $14000.0 in Q3 2023.
Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023) Analysis & Trends
Sol-Gel Technologies (SLGL) has 2 years of Other Non Operating Income data on file, last reported at $2.1 million in Q4 2023.
- Other Non Operating Income for Q4 2023 came in at $2.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $2.6 million (changed N/A YoY), and the FY2025 annual result was $1.4 million, down 1.6% from the prior year.
- Other Non Operating Income rose to $2.1 million in Q4 2023 per SLGL's latest filing, from $14000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $2.1 million in Q4 2023 and troughed at -$30000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.05 Mn |
| Sep 30, 2023 | 14,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Sep 30, 2021 | 554,000.00 |